Literature DB >> 24629562

Obesity-associated mechanisms of hepatocarcinogenesis.

Raffi Karagozian1, Zoltán Derdák2, György Baffy3.   

Abstract

Obesity has been recognized as a key component of the metabolic syndrome, a cluster of risk factors associated with diabetes and cardiovascular morbidity. In addition, obesity has been linked to higher frequency of cancers in a variety of tissues including the liver. Liver cancer most often occurs as hepatocellular carcinoma (HCC) complicating cirrhosis due to chronic viral infection or toxic injury and remains the third leading cause of cancer death in the world. However, HCC is increasingly diagnosed among individuals with obesity and related disorders. As these metabolic conditions have become globally prevalent, they coexist with well-established risk factors of HCC and create a unique challenge for the liver as a chronically diseased organ. Obesity-associated HCC has recently been attributed to molecular mechanisms such as chronic inflammation due to adipose tissue remodeling and pro-inflammatory adipokine secretion, ectopic lipid accumulation and lipotoxicity, altered gut microbiota, and disrupted senescence in stellate cells, as well as insulin resistance leading to increased levels of insulin and insulin-like growth factors. These mechanisms synergize with those occurring in chronic liver disease resulting from other etiologies and accelerate the development of HCC before or after the onset of cirrhosis. Increasingly common interactions between oncogenic pathways linked to obesity and chronic liver disease may explain why HCC is one of the few malignancies with rising incidence in developed countries. Better understanding of this complex process will improve our strategies of cancer prevention, prediction, and surveillance. Published by Elsevier Inc.

Entities:  

Keywords:  Adipose tissue remodeling; Hepatocellular carcinoma; Insulin resistance; Lipotoxicity; Nonalcoholic fatty liver disease

Mesh:

Substances:

Year:  2014        PMID: 24629562     DOI: 10.1016/j.metabol.2014.01.011

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  65 in total

Review 1.  Is That Possible to Stop or Cease the NASH to Turn into HCC?

Authors:  Ahmet Uygun
Journal:  J Gastrointest Cancer       Date:  2017-09

2.  Health behaviors of Korean adults with hepatitis B: Findings of the 2016 Korean National Health and Nutrition Examination Survey.

Authors:  Yu-Hyeon Yi; Yun-Jin Kim; Sang-Yeoup Lee; Byung-Mann Cho; Young-Hye Cho; Jeong-Gyu Lee
Journal:  World J Gastroenterol       Date:  2018-07-28       Impact factor: 5.742

3.  Short- and Long-Term Outcomes of Liver Resection for Intrahepatic Cholangiocarcinoma Associated with the Metabolic Syndrome.

Authors:  Christian Hobeika; François Cauchy; Nicolas Poté; Pierre-Emmanuel Rautou; François Durand; Olivier Farges; Safi Dokmak; Valérie Vilgrain; Maxime Ronot; Valérie Paradis; Olivier Soubrane
Journal:  World J Surg       Date:  2019-08       Impact factor: 3.352

4.  Silymarin suppresses HepG2 hepatocarcinoma cell progression through downregulation of Slit-2/Robo-1 pathway.

Authors:  Nuriye Ezgi Bektur Aykanat; Sedat Kacar; Serife Karakaya; Varol Sahinturk
Journal:  Pharmacol Rep       Date:  2020-01-08       Impact factor: 3.024

5.  Body Mass Index, Waist Circumference, Diabetes, and Risk of Liver Cancer for U.S. Adults.

Authors:  Peter T Campbell; Christina C Newton; Neal D Freedman; Jill Koshiol; Michael C Alavanja; Laura E Beane Freeman; Julie E Buring; Andrew T Chan; Dawn Q Chong; Mridul Datta; Mia M Gaudet; J Michael Gaziano; Edward L Giovannucci; Barry I Graubard; Albert R Hollenbeck; Lindsey King; I-Min Lee; Martha S Linet; Julie R Palmer; Jessica L Petrick; Jenny N Poynter; Mark P Purdue; Kim Robien; Lynn Rosenberg; Vikrant V Sahasrabuddhe; Catherine Schairer; Howard D Sesso; Alice J Sigurdson; Victoria L Stevens; Jean Wactawski-Wende; Anne Zeleniuch-Jacquotte; Andrew G Renehan; Katherine A McGlynn
Journal:  Cancer Res       Date:  2016-10-15       Impact factor: 12.701

Review 6.  p53 in liver pathologies-taking the good with the bad.

Authors:  Meital Charni; Noa Rivlin; Alina Molchadsky; Ronit Aloni-Grinstein; Varda Rotter
Journal:  J Mol Med (Berl)       Date:  2014-11-19       Impact factor: 4.599

7.  Signal transducer and activator of transcriptions (STATs)-at the crossroads of obesity-linked non-alcoholic steatohepatitis and hepatocellular carcinoma.

Authors:  Nivida Mishra; Suresh Mishra
Journal:  Hepatobiliary Surg Nutr       Date:  2019-08       Impact factor: 7.293

8.  Risk factors for hepatocellular carcinoma (HCC) in the northeast of the United States: results of a case-control study.

Authors:  Yi Shen; Harvey Risch; Lingeng Lu; Xiaomei Ma; Melinda L Irwin; Joseph K Lim; Tamar Taddei; Karen Pawlish; Antoinette Stroup; Robert Brown; Zhanwei Wang; Wei Jia; Linda Wong; Susan T Mayne; Herbert Yu
Journal:  Cancer Causes Control       Date:  2020-02-14       Impact factor: 2.506

9.  Self-reported eating speed in relation to non-alcoholic fatty liver disease in adults.

Authors:  Saehyun Lee; Byung-Joon Ko; Younghoon Gong; Kyungdo Han; Anna Lee; Byoung-Duck Han; Yeo Joon Yoon; Siyoung Park; Jung-Hyun Kim; Christos S Mantzoros
Journal:  Eur J Nutr       Date:  2015-02-04       Impact factor: 5.614

10.  Expression of connective tissue growth factor in the livers of non-viral hepatocellular carcinoma patients with metabolic risk factors.

Authors:  Keiichi Akahoshi; Shinji Tanaka; Kaoru Mogushi; Shu Shimada; Satoshi Matsumura; Yoshimitsu Akiyama; Arihiro Aihara; Yusuke Mitsunori; Daisuke Ban; Takanori Ochiai; Atsushi Kudo; Shigeki Arii; Minoru Tanabe
Journal:  J Gastroenterol       Date:  2016-01-06       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.